ube2f Antibody

What is UBE2F and what is its function in cellular systems?

UBE2F (NEDD8-conjugating enzyme UBE2F, also known as NCE2) is an E2 conjugating enzyme in the protein neddylation pathway. It accepts the ubiquitin-like protein NEDD8 from the UBA3-NAE1 E1 complex and catalyzes its covalent attachment to substrate proteins . UBE2F specifically pairs with RBX2/SAG E3 ligase to mediate CUL5 neddylation, whereas UBE2M (another neddylation E2) typically pairs with RBX1 to regulate neddylation of CUL1-4 .

The UBE2F-mediated neddylation activates Cullin-RING ligase 5 (CRL5), which subsequently ubiquitylates substrate proteins for proteasomal degradation. A key substrate of CRL5 is NOXA, a pro-apoptotic protein . Through this regulatory mechanism, UBE2F plays crucial roles in cancer cell survival and treatment resistance.

What are the typical applications for UBE2F antibodies in research?

UBE2F antibodies have been validated for multiple experimental applications:

Most commercial UBE2F antibodies react with human, mouse, and rat samples, making them versatile tools for comparative studies across species .

How can I validate the specificity of a UBE2F antibody for my research?

Comprehensive validation of UBE2F antibody specificity should include:

• Positive control samples: Use cell lines known to express UBE2F such as A375 cells, Jurkat cells, or lung cancer cell lines (H358, A427)

• Negative controls: Utilize UBE2F knockout cell lines (commercially available, e.g., ab265339 from Abcam)

• Western blot analysis: Confirm a single band at the expected molecular weight of approximately 21 kDa

• Knockdown verification: Perform siRNA or shRNA-mediated knockdown of UBE2F and verify reduced antibody signal

• Multiple antibody comparison: Use antibodies targeting different UBE2F epitopes to confirm consistency of results

• Cross-reactivity assessment: Test for potential cross-reactivity with UBE2M, which shares some structural similarities

What are the optimal experimental conditions for detecting UBE2F by Western blot?

For optimal Western blot detection of UBE2F:

• Protein loading: 20-30 μg of total protein per lane

• Antibody dilution: 1:500-1:2000 for primary antibody

• Incubation conditions: Overnight at 4°C for primary antibody

• Expected molecular weight: Look for a band at approximately 21 kDa

• Controls: Include lysates from UBE2F knockout or knockdown samples

• Detection methods: Both chemiluminescence and fluorescence-based detection systems are effective

• Normalization: Use housekeeping proteins like GAPDH or β-actin as loading controls

When troubleshooting, consider that UBE2F levels may vary significantly between cell types, and the protein is subject to stress-induced regulation .

How can I optimize immunohistochemistry protocols for UBE2F detection in tissue samples?

For optimal IHC results when analyzing UBE2F expression:

• Tissue fixation: Standard formalin fixation and paraffin embedding works well

• Antigen retrieval: Use TE buffer pH 9.0 as primary choice, or alternatively citrate buffer pH 6.0

• Antibody dilution: Start with 1:50-1:200 dilution and optimize based on signal intensity

• Incubation time: Overnight at 4°C typically yields best results

• Positive control tissues: Human skin tissue has been validated for UBE2F detection

• Blocking: Use serum-free protein block to reduce background

• Signal amplification: Consider polymer-based detection systems for enhanced sensitivity

Remember that UBE2F expression varies between tissue types and may be upregulated in cancer tissues compared to normal tissues .

How can I investigate the functional differences between UBE2F and UBE2M in my research?

Despite both being neddylation E2 enzymes, UBE2F and UBE2M have distinct functions that can be studied through:

• Substrate specificity analysis: UBE2F specifically neddylates CUL5, while UBE2M targets CUL1-4

• E3 partner discrimination: UBE2F pairs with RBX2/SAG, whereas UBE2M pairs with RBX1

• Differential knockdown experiments: Compare phenotypes after UBE2F versus UBE2M knockdown

• Transcriptome analysis: Examine non-overlapping gene expression patterns following knockdown of each enzyme

• Stress response studies: UBE2M is stress-inducible and can act as a dual E2 for CUL3 neddylation and Parkin E3 to promote UBE2F degradation

• DNA damage sensitivity: Cells depleted of UBE2M, but not UBE2F, show increased sensitivity to DNA-damaging agents

This regulatory axis between UBE2M and UBE2F represents an important control mechanism in cellular neddylation pathways.

What methodologies can effectively study the UBE2F-CRL5-NOXA regulatory axis in cancer research?

To investigate this important regulatory pathway:

• Co-immunoprecipitation: Detect protein interactions between UBE2F, SAG/RBX2, CUL5, and NOXA

• Neddylation assays: Examine CUL5 neddylation status using antibodies specific for neddylated proteins

• Ubiquitylation assays: Assess NOXA ubiquitylation status after manipulation of UBE2F levels

• Apoptosis assays: Measure cell death markers (PARP and caspase-3 cleavage, DNA fragmentation) after modulating the axis components

• Rescue experiments: Determine if NOXA knockdown can rescue the effects of UBE2F inhibition

• Small molecule inhibitors: Use specific inhibitors like HA-9104 that target the UBE2F-CRL5 axis

• In vivo xenograft models: Evaluate tumor growth following manipulation of this regulatory axis

This approach can reveal important insights into cancer cell survival mechanisms and potential therapeutic targets.

How can UBE2F antibodies be utilized in studies of platinum resistance in cancer?

UBE2F has been implicated in platinum resistance mechanisms in lung cancer. Methodological approaches include:

• Expression analysis: Compare UBE2F levels in platinum-sensitive versus resistant cancer cells using antibody-based methods

• Treatment response monitoring: Track UBE2F expression before and after platinum treatment using Western blot analysis

• Mechanism investigation: Study how platinum treatment impairs UBE2F degradation by examining the association between UBE2F and RBX1

• Combination therapy assessment: Evaluate the effects of UBE2F knockdown or inhibition in combination with platinum agents

• Patient sample correlation: Use IHC with UBE2F antibodies to correlate expression with treatment response in clinical samples

• CUL5 neddylation analysis: Monitor how platinum treatment affects UBE2F-mediated CUL5 neddylation and subsequent CRL5 activity

These approaches can identify potential strategies to overcome platinum resistance in cancer therapy.

What are common challenges when working with UBE2F antibodies and how can they be addressed?

Researchers may encounter several challenges when using UBE2F antibodies:

• Cross-reactivity: UBE2F belongs to the ubiquitin-conjugating enzyme family, which has multiple homologous members. Validate specificity using knockout controls .

• Low endogenous expression: Some cell types express low levels of UBE2F. Consider using enrichment techniques or more sensitive detection methods.

• Dynamic regulation: UBE2F levels can change rapidly under stress conditions or treatments . Include appropriate time-course experiments.

• Degradation during sample preparation: Add protease inhibitors to all buffers and keep samples cold.

• Antibody batch variation: Validate each new lot of antibody against previous lots or reference samples.

• Background in immunostaining: Optimize blocking conditions and antibody dilutions; consider using monoclonal antibodies for higher specificity .

How should UBE2F antibodies be stored and handled to maintain optimal performance?

For maximum antibody performance and longevity:

• Storage temperature: Store at -20°C for long-term storage

• Short-term storage: For frequent use, store at 4°C for up to one month

• Avoid freeze-thaw cycles: Aliquot antibodies to minimize freeze-thaw cycles

• Buffer composition: Most UBE2F antibodies are supplied in PBS with glycerol (40-50%) and sodium azide (0.02-0.05%)

• Working dilutions: Prepare fresh working dilutions on the day of experiment

• Safety considerations: Note that many antibody preparations contain sodium azide, which is toxic and should be handled accordingly

Following these guidelines will help maintain antibody performance throughout your research project.

How are UBE2F antibodies being used to develop potential cancer therapeutics?

UBE2F antibodies have become valuable tools in cancer therapeutic development:

• Target validation: UBE2F is overexpressed in lung cancer and correlates with poor survival in lung adenocarcinoma patients

• Small molecule screening: Antibodies are used to validate the effects of small molecule inhibitors like HA-9104 on UBE2F protein levels and function

• Combination therapy development: UBE2F antibodies help assess how UBE2F inhibition can sensitize cancer cells to platinum-based chemotherapy or radiation

• Mechanism studies: Investigating how UBE2F promotes cancer cell survival through CRL5 activation and NOXA degradation

• Biomarker potential: Evaluating UBE2F as a prognostic biomarker in cancer through antibody-based detection methods

The development of small molecule inhibitors targeting the UBE2F-CRL5 axis represents a promising direction for cancer therapeutics, particularly for platinum-resistant tumors .

What are recent methodological advancements in studying protein neddylation using UBE2F antibodies?

Recent advances include:

• Proximity ligation assays: For detecting UBE2F-substrate interactions in situ

• Mass spectrometry-based approaches: Identifying novel UBE2F substrates and interaction partners

• CRISPR-based genetic screens: Identifying synthetic lethal interactions with UBE2F

• Single-cell analysis: Examining UBE2F expression heterogeneity within tumors

• Patient-derived organoids: Testing UBE2F inhibition strategies in more clinically relevant models

• Combining radiotherapy with UBE2F inhibition: UBE2F inhibitors like HA-9104 can enhance radiosensitization in lung cancer models

These methodological advances are expanding our understanding of UBE2F biology and its potential as a therapeutic target.